MedTrace Logo

The SMART CART Study: Health Information Technology

NCT04051216 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 148

Last updated 2024-03-22

No results posted yet for this study

Summary

This study evaluates the feasibility of using two information technology tools in patients undergoing Chimeric Antigen Receptor T-cell (CART) therapy and other Cytokine Release Syndrome (CRS)-eliciting treatments such as CD123 BITE. The first is an Apple iPad® application called the BMT Roadmap, which shows information about the participant's health. The second is a wearable activity monitoring device. Health information technology tools such as Roadmap system and the activity monitoring device may enable caregivers and patients to become more active participants in their healthcare.

Conditions

  • Leukemia, Acute
  • Leukemia, Lymphoblastic

Interventions

BEHAVIORAL

Education information system

Participants will receive a mobile tablet as an educational intervention

OTHER

Activity monitor

Participants will receive at least 1 of 4 activity monitoring devices

OTHER

Interview

Participants will be interviewed about their experience using the device(s)

OTHER

Survey Administration

Participants will receive surveys

OTHER

Laboratory Biomarker Analysis

Correlative studies

Sponsors & Collaborators

Principal Investigators

  • Sung Won Choi, MD, MS · University of Michigan

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
3 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-12-20
Primary Completion
2023-08-25
Completion
2023-11-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04051216 on ClinicalTrials.gov